Sanofi Healthcare India Gets CDSCO Panel Nod To study SAR441566

Written By : Dr. Divya Colin |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-05-05T17:45:00+05:30 | Updated On 5 May 2025 5:45 PM IST

CDSCO Panel Approves Fabrazyme Label Update, Asks Sanofi to Submit EMA Nod

New Delhi: SanofiHealthcare India has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial of the drug SAR441566.

This came after the firm presented phase II clinical study protocol no. DRI17822 Amendment number 01 Version 01 Dated 19 Dec 2024.

SAR-441566 is under development for the treatment of inflammatory bowel disease, rheumatoid arthritis and plaque psoriasis. It is administered through the oral route. The drug candidate acts by targeting TNF.

SAR441566 is a small molecule inhibitor of tumor necrosis factor (TNF) signaling, currently under development for treating inflammatory conditions like Crohn's disease, rheumatoid arthritis, and plaque psoriasis.

At the recent SEC meeting for gastroenterology and hepatology held on 18th March 2025, the expert panel reviewed phase II clinical study protocol no. DRI17822 Amendment number 01 Version 01 Dated 19 Dec 2024.

After detailed deliberation, the committee recommended the grant of permission to conduct the trial as presented by the firm.

Also Read:CDSCO panel grants clearance to Morepen Labs to conduct BE studies for fatty liver disease drug Resmetirom

sanofi healthcare indiacdscoSAR441566

Dr. Divya Colin

Doctor of Pharmacy

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751